U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
September 09, 2026
September 09, 2026
WHIPPANY, New Jersey, Sept. 9 [Category: BizPharmaceuticals] -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, posted the following news:
* * *
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO(r) (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
*
* First-line approval of HYRNUO(r) (sevabertinib) for patients with advanc . . .
* * *
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO(r) (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
*
* First-line approval of HYRNUO(r) (sevabertinib) for patients with advanc . . .